The pivotal role of BTK in BCR signaling and B cell lymphoma pathogenesis has led to the development of BTK inhibitors as targeted therapies, which are now a frontline therapy for many lymphoma subtypes. Here, BCR is linked to B-cell non-Hodgkin lymphoma.